posted on 2019-09-18, 14:25authored byAK Bergmann, V Fataccioli, G Castellano, N Martin-Garcia, L Pelletier, O Ammerpohl, J Bergmann, J Bhat, EC-DS Pau, JI Martín-Subero, AB Moffitt, A Valencia, H-H Oberg, D Wesch, S Jayne, MJS Dyer, D Kabelitz, P Gaulard, R Siebert
[First paragraph] Hepatosplenic T–cell lymphoma (HSTL) is a malignancy with an unfavorable outcome mainly affecting young adults. To discover genes showing altered DNA-methylation in HSTL we performed array-based DNA methylation profiling of HSTL cells from 11 patients and compared the findings to those obtained from purified non-neoplastic ab-positive and gd-positive T cells. The procedure identified 1,339 hypermethylated and 2,774 hypomethylated CpG-loci in HSTL compared to controls. DNA methylation changes in HSTL were enriched for regulatory elements, like enhancers. Considering the top 100 differentially-methylated CpGs from various subset comparisons, we identified eight consistently hypermethylated genes (BCL11B, CD5, CXCR6, GIMAP7, LTA, SEPT9, UBAC2, UXS1) and four consistently hypomethylated genes (ADARB1, NFIC, NR1H3, ST3GAL3) in HSTL.
Funding
Funding: this work was funded by the European Union’s Seventh
Framework Program through the Blueprint Consortium (grant agreement 282510). MJSDs work was supported by the Leicester
Experimental Cancer Medicine Centre (C325/A15575 Cancer
Research UK/UK Department of Health). PG’s work was supported
by a grant from the Fondation pour la Recherche Médicale, grant number “DEQ20160334875”. RS’ work was supported by the DFG in
the framework of the SFB1074.
History
Citation
Haematologica, 2019, 104 (3), pp. e104-e107
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Cancer Research Centre
Version
VoR (Version of Record)
Published in
Haematologica
Publisher
Ferrata Storti Foundation, European Hematology Association